Kisspeptin-10

Common side effects:

• Injection site reactions including redness or swelling
• Mild flushing or temporary temperature fluctuations
• Headaches following administration
• Nausea or mild gastrointestinal discomfort

Rare or serious side effects:

• Hormonal imbalances with prolonged or improper use
• Potential overstimulation of the hypothalamic-pituitary-gonadal axis
• Unintended alterations in insulin secretion and glucose metabolism

Receptor activation is the primary mechanism by which the Kisspeptin-10 peptide exerts its biological effects. It acts as a high-affinity ligand for the G-protein coupled receptor 54 (GPR54), also known as the KISS1 receptor. Upon binding, it triggers a cascade of intracellular signaling pathways, most notably stimulating the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This targeted activation is crucial for regulating the downstream release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Secondary signaling pathways mediate the diverse systemic Kisspeptin-10 benefits observed outside the reproductive system. In bone tissue, it activates Dusp18-mediated dephosphorylation of Src to inhibit osteoclast activity and prevent bone loss (Li Z et al., 2024). Furthermore, it modulates cellular senescence and apoptosis in various tissues by regulating SIRT1/p53/p21 and Wnt/β-catenin signaling networks (Qiu J et al., 2025; Guo C et al., 2025).

Discovery and isolation of kisspeptins originated in 1996 when researchers identified the KISS1 gene in Hershey, Pennsylvania—inspiring the name "kisspeptin" after the town's famous chocolate Kisses. Kisspeptin-10 is the shortest endogenous cleavage product of the primary 145-amino acid precursor protein that still retains full biological activity at the GPR54 receptor. Its identification revolutionized the understanding of reproductive endocrinology and pubertal onset.

Clinical development has primarily focused on its role in reproductive health and metabolic function. Several Phase 3 clinical trials have investigated its effects on pubertal onset in boys and hypothalamic-pituitary-gonadal axis responsiveness in men (NCT03286517; NCT03315325). Currently, Kisspeptin-10 remains a research-only synthetic hormone and has not received FDA approval for medical use or human consumption.